Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15164295 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2GAALMNAMAPTPOLB | |
| SCHEMBL14768473 | 0.85 | LMNA (0.51) | SMN1; SMN2GAALMNAALDH1A1TSHR | |
| SCHEMBL1514800 | 0.79 | LMNA (0.36) | SMN1; SMN2LMNAHPGD | |
| SCHEMBL15164292 | 0.79 | LMNA (0.46) | SMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL15170753 | 0.78 | LMNA (0.41) | SMN1; SMN2LMNAPOLBALDH1A1HSD17B10 | |
| SCHEMBL4550627 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2GAALMNAPOLBALDH1A1 | |
| SCHEMBL24961141 | 0.74 | LMNA (0.32) | SMN1; SMN2LMNA | |
| SCHEMBL21982819 | 0.73 | HPGD (0.33) | SMN1; SMN2LMNAMAPTALDH1A1TSHR | |
| SCHEMBL25474851 | 0.72 | ATM (0.37) | SMN1; SMN2LMNAPOLBHPGD | |
| SCHEMBL15504586 | 0.72 | ATM (0.37) | SMN1; SMN2LMNAPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B1 | SMN1; SMN2 832/4885GAA 721/4885LMNA 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.